Invesco Pharmaceuticals ETF
PJP
86 hedge funds and large institutions have $52.6M invested in Invesco Pharmaceuticals ETF in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 32 reducing their positions, and 8 closing their positions.
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
4% more funds holding
Funds holding: 83 → 86 (+3)
0.28% more ownership
Funds ownership: 19.63% → 19.91% (+0.28%)
1% less capital invested
Capital invested by funds: $53.3M → $52.6M (-$683K)
69% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGCM
Joseph Group Capital Management
Columbus,
Ohio
|
+$1.99M |
| 2 |
CRI
Commonwealth Retirement Investments
Richmond,
Virginia
|
+$1.46M |
| 3 |
PAM
Peak Asset Management
Louisville,
Colorado
|
+$476K |
| 4 |
JP Morgan Chase
New York
|
+$281K |
| 5 |
KDA
Kraft Davis & Associates
St. Louis,
Missouri
|
+$259K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.03M |
| 2 |
Goldman Sachs
New York
|
-$823K |
| 3 |
Vontobel Holding
Zurich,
Switzerland
|
-$543K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$468K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$378K |
PJP Hedge Fund Activity: Q4 2023 in Review
86 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q4 2023, worth a combined $52.6M — down 1.3% from $53.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PJP positions and 8 closed out — a net gain of 4 holders — while 10 added to existing stakes and 32 trimmed.
The largest buyer was Joseph Group Capital Management, opening a new position worth an estimated $1.99M. The largest seller was UBS Group, cutting an estimated $4.03M.
- 86 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q4 2023, up from 83 in Q3 2023.
- Funds reported $52.6M of Invesco Pharmaceuticals ETF stock for Q4 2023, down 1.3% quarter-over-quarter.
- 12 funds opened new Invesco Pharmaceuticals ETF positions in Q4 2023 and 8 closed out, a net change of +4 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q4 2023 was Joseph Group Capital Management, an estimated $1.99M added.
- The largest Invesco Pharmaceuticals ETF seller in Q4 2023 was UBS Group, an estimated $4.03M sold.
Based on aggregated 13F filings for Q4 2023.